The report examines the likely impact of the indicative drug budgets for family doctors and the government's general practice fund holding initiative in Britain. The authors believe that the new arrangements will sharpen price competition in the UK medicines market, and welcome this. The study also reports on recent European proposals to extend 'on-the-market' pharmaceutical patent terms in Europe to 16 years. The report looks to the future of medicines-spending and the role of pharmacists.